Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | terminated | Phase 1 | 78 | Fusion Pharmaceuticals Inc.INDUSTRY | 3 | Jan 7, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03215719 |
| Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma |
| recruiting |
| Phase 2 |
| 120 |
| NYU Langone HealthOTHER |
| 1 |
| Jan 6, 2026 |
| clinicaltrials |
| NCT05482880 | Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region | completed | — | 78 | Maastricht University Medical CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT07274852 | A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07320690 | De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma(Neo-Margin) | not yet recruiting | Phase 3 | 356 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04801472 | Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)(OPPIDOM) | terminated | N/A | 8 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03896412 | Detection of Circulating Tumor DNA in p16- Locally Advanced Head Neck Squamous Cell Carcinoma(PERSO-NECK) | completed | N/A | 40 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04031534 | Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma(HYPONECK) | completed | Phase 2 | 16 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04528420 | Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer(OPTINECK) | recruiting | N/A | 138 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05934929 | Contribution of Residual Tumour DNA Testing on the Surgical Bed(MARGINS) | active not recruiting | N/A | 31 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04124198 | Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma(QoLATI) | active not recruiting | N/A | 138 | Christian von BuchwaldOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07232524 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 16 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04490564 | Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma | completed | — | 135 | Pharmassist LtdINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07190755 | Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinoma (HNSCC)(WEBNECK) | recruiting | N/A | 192 | Centre Henri BecquerelOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07310771 | Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II | not yet recruiting | Phase 2 | 23 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 30, 2025 | clinicaltrials |
| NCT01827956 | Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms(FCR-VADS) | completed | — | 121 | Institut BergoniéOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT04045496 | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07306546 | Effectiveness of Hydrogen Water Intervention on Acute Oral Inflammation, Oral Microbiota, and Pain Following Free Flap Reconstruction in Patients With Oral Cancer | not yet recruiting | N/A | 36 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT05183048 | Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma | recruiting | Early Phase 1 | 14 | University of Alabama at BirminghamOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT06659146 | Thermotherapy in Addition to SOC Palliative Radiotherapy(ThermoRad wIRA) | recruiting | N/A | 60 | King's College LondonOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06603155 | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC) | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05668949 | Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 17, 2025 | clinicaltrials |
| NCT04445064 | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.(HN1901) | terminated | Phase 2 | 17 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06606028 | Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma | recruiting | — | 250 | University of California, San FranciscoOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04811027 | Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC(TACTI-003) | completed | Phase 2 | 171 | Immutep S.A.S.INDUSTRY | 9 | Dec 11, 2025 | clinicaltrials |
| NCT05793151 | Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy(ENDURE) | recruiting | N/A | 532 | Medical University of South CarolinaOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05845307 | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck | withdrawn | Early Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT03381183 | IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma | completed | Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07267286 | Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005） | active not recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06730412 | ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)(Clear-HPVca) | completed | — | 103 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06159621 | CD40 Agonist and PD-1 Inhibitor in HNSCC | active not recruiting | Phase 1 | 27 | University of PennsylvaniaOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05433116 | Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC | active not recruiting | Phase 2 | 50 | Universität des SaarlandesOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259915 | Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck(MULTINECK) | not yet recruiting | N/A | 152 | Centre Henri BecquerelOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT05383170 | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers(Catalyst) | completed | Phase 1 / Phase 2 | 6 | Cytovation ASINDUSTRY | 5 | Nov 28, 2025 | clinicaltrials |
| NCT06107686 | A Study of YL202 in Selected Patients With Advanced Solid Tumors | recruiting | Phase 2 | 200 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05333523 | Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.(PRIMO) | recruiting | Phase 3 | 242 | Radboud University Medical CenterOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06332755 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC(LB-LR1109) | recruiting | Phase 1 | 76 | LG ChemINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07081984 | Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors | recruiting | Phase 1 | 12 | TherornaINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 7, 2026source: clinicaltrials